Aiming at IVD's 100 billion blue ocean, Yingsheng Bio, a pioneer in clinical mass spectrometry, announced the completion of several hundred million B rounds of financing
Inputtime：2020-11-12 16:42:11 Views：
Recently, Shandong Yingsheng Biotechnology Co., Ltd. completed Series B financing of several hundred million yuan, which was led by Gaochun Venture Capital. Old shareholders such as Chenling Capital, Sunshine Ronghui Capital, Huimei Capital and Qianhai Parent Fund continued to raise funds, Yuansheng Venture Capital and Haoyue Capital acted as the exclusive financial advisor. Earlier, the company was invested by famous institutions such as Sanze Venture Capital, Yahui Investment and Xiamen Jianfa. After the completion of this round of financing, Yingsheng Bio plans to accelerate the market expansion in the field of mass spectrometry, consolidate the industrial chain and technical team, maintain the leading edge in product development, and on this basis, build a full range of products for clinical mass spectrometry applications and shape IVD brand enterprises.
Yingsheng Bio, established in 2009, is a pioneer in technology development, quality control and technical services in the field of clinical mass spectrometry in China, focusing on the field of clinical mass spectrometry for more than ten years, and is also a high-tech enterprise integrating R&D, production, sales and third-party medical testing services. Yingsheng built a leading domestic gene detection platform and mass spectrometry detection platform around metabonomics and genomics, covering the fields of birth defect screening, disease prevention and human health services, and won 15 national patents and 6 software copyrights, participated in the construction of 3 industry standards and 1 national standard, and passed ISO13485 and ISO9001 quality management system certification. It is the backbone enterprise of the key biomedical engineering industrial cluster in the "13 th Five-Year Plan" of science and technology innovation in Shandong Province.
The mass spectrometry market is known as "the next IVD billion blue ocean"
Compared with traditional detection methods, mass spectrometry technology has the advantages of high sensitivity, high specificity, high accuracy, wide linear range and high throughput, and can be applied to clinical biochemical test, clinical immunological test, clinical microbiological test and clinical molecular biological diagnosis, etc. It is called the next billion blue ocean market in the field of in vitro diagnosis. Mass spectrometry has been widely carried out in developed countries in Europe and America. According to statistics, there are more than 400 mass spectrometry testing items serving clinical diagnosis and treatment. Compared with foreign countries, there is still a big gap between domestic mass spectrometry industry and developed countries. Most markets are occupied by foreign brands. Mass spectrometry technology has risen to the core technology of national strategy. With the joint efforts of industry, scientific research and medical circles, the localization process of mass spectrometry is accelerating. Yingsheng Bio is the first to launch a complete one-stop clinical mass spectrometry solution, which meets the five major elements of clinical mass spectrometry development (mass spectrometer+reagent+pretreatment+data+service). The platform will be composed of many NMPA registered products pioneered by Yingsheng in China, including fully automatic sample pretreatment equipment, medium and high-end domestic LC-MS/MS,ICP-MS,MALDI-TOF system equipment, and clinical mass spectrometry application series kit products.
Mr. Feng Zhen, Chairman of Yingsheng Bio, said
Thanks to gaoling venture capital, chenling capital, Yuansheng venture capital, sunshine ronghui capital, huimei capital and qianhai parent fund for their recognition of yingsheng, and also thanks to haoyue team for their professionalism and efficiency in the financing process. After this round of financing, Yingsheng Bio will enter a period of rapid development in an all-round way, with continuous improvement in instrument manufacturing, clinical application research and development, intelligent pretreatment development, etc., and comprehensively promote the rapid development of China's clinical mass spectrometry industry.
Mr. Yi Nuoqing, co-chief investment officer of Gaochun Capital and head of biomedicine and medical devices of Gaochun Venture Capital, said
Mass spectrometry, represented by new screening, vitamins, blood concentration and trace elements, has gradually emerged in the in vitro diagnosis industry because of its advantages in detection accuracy, sensitivity and flux. However, compared with developed countries, there is still a big gap in the popularity of clinical mass spectrometry in China. Yingsheng Bio has built an integrated IVD solution around the clinical mass spectrometry application, and comprehensively solved the pain points of mass spectrometry popularization in hospitals. In addition to pioneering 14 detection reagents for full spectrum vitamins, Yingsheng Bio is ahead of the industry in mass spectrometer, pretreatment equipment and application and certification layout of mass spectrometry reagents, and is the leader of clinical mass spectrometry in China and the builder of industry standards. Feng Zhen, the founder, has deep accumulation and broad vision in the field of mass spectrometry. We expect Yingsheng Bio to continue to succeed in the field of clinical mass spectrometry, provide better application of mass spectrometry for patients and the market, and finally become a benchmark enterprise in the field of clinical mass spectrometry in China.
Mr. Zhu Tianqi, Managing Director of Chende Capital, said
Clinical mass spectrometry is the blue ocean market of in vitro diagnosis industry, and it is also the systematic investment field of Chende Capital. We believe that clinical mass spectrometry detection will be extended from reproduction, heredity, metabolism and other fields to many directions, which will continue to produce heavy applications and occupy an important share in the whole in vitro diagnosis market. Yingsheng Bio has a practical, efficient and trustworthy management team. Chende is optimistic that Yingsheng will become the leader of China's clinical mass spectrometry industry, and expects Yingsheng to continuously introduce high-quality solutions to better meet clinical needs and promote the development of the industry.
Dr. Lin Yi, managing partner of Yuansheng Venture Capital, said
We have always been firmly optimistic about the huge potential blank market of mass spectrometry technology platform in domestic clinical diagnosis, and also firmly optimistic about the core competitiveness built by Yingsheng Bio in the complete combination of mass spectrometry products and services. After several years of market baptism in China, the development of clinical mass spectrometry project has been pushed forward in depth, from leading by tertiary hospitals to spreading to secondary hospitals, from traditional vitamin and neonatal screening projects to more challenging and larger market application fields such as hormones, blood drug concentration and metabonomics. We are very pleased to see that Yingsheng Bio has been highly recognized by well-known funds such as Gaochun Venture Capital, Chenling Capital, Sunshine Convergence Capital and Qianhai Parent Fund, and look forward to working with new shareholders to help Yingsheng Bio develop a new world in this 100 billion blue ocean.
Mr. Shi Wei, managing partner of Sunshine Ronghui Capital, said
Innovation and application of genomics, proteomics and metabolomics are the key investment directions of Sunshine Fusion Capital. The unique advantages of mass spectrometry make it irreplaceable for clinical examination. Yingsheng management team deeply understood the pain points of clinical application of mass spectrometry, and made a deep impression on the complete construction of IVD integrated solution of mass spectrometry and the exploration and practice of commercial promotion mode. It is a great honor to participate in the development of the company. With the common growth of the company, we expect Yingsheng to achieve greater success and lead the development of the industry.
Mr. Li Yishi, a partner of Haoyue Capital, said
We are honored to assist Yingsheng Bio to complete this round of financing. Haoyue Capital has conducted in-depth research in the direction of clinical mass spectrometry, and this field is the golden track that will usher in explosive growth in the in vitro diagnosis market. Yingsheng Bio has solved one of the most obvious pain points of clinical mass spectrometry through standardized sample pretreatment. The developed 14 vitamins and new screening products are very distinctive, and have global market and product cooperation resources. The founder Feng Zong and his team have a deep understanding of the Chinese clinical mass spectrometry market. With the help of capital, we believe that Yingsheng Bio will continue to lead the clinical mass spectrometry track and provide one-stop clinical mass spectrometry solutions for hospitals. We are confident that we will continue to help Yingsheng's follow-up financing and accompany customers to grow rapidly.
About Gaochun Venture Capital
Gaochun Venture Capital is a venture capital fund of Gaochun, which focuses on early innovative companies. It mainly specializes in venture capital in four major areas: biomedicine and medical devices, software and hard technology, consumer internet and technology, and emerging consumer brands and services. The fields of biomedicine and medical devices have always been the key investment direction of Gaochun. Over the past ten years, Gaochun has invested in more than 200 excellent enterprises such as biomedicine, medical devices and medical services. We hope to work with enterprises, be friends of time, and jointly promote the innovation and development of enterprises in the big health field to benefit more patients.
About Chende Capital Chende
Capital is an investment institution focusing on life sciences and medical technology. It manages a number of US dollar funds and RMB funds, with a management scale of over RMB 4 billion. Chende Capital is managed and operated by a professional team with senior medical industry background, and is committed to building top enterprises in the medical field and creating the best returns for investors.
About Sunshine Fusion Capital
Sunshine Ronghui Capital was established in 2015, and it is the first pilot unit in China's insurance industry to set up private equity fund management companies. Since its inception, Ronghui Capital has been built according to market-oriented and professional standards, and has become one of the most outstanding insurance fund management institutions. The total assets under management of Sunshine Convergence Capital now exceed 18 billion, and the invested enterprises include Mindray Medical, Yuyue Medical, Lepu Bio, Jiahe Bio, Sansheng Pharmaceutical, Shengnuo Bio, Saide Sunshine, Ruipeng Pet Hospital, Ant Group, Jingdong Digital Branch, Shangtang Technology, Yisiwei and so on.
About Huimei Capital HM
Capital is a vertical fund focusing on medical and health investment. Relying on the ecological advantages of the largest private equity fund in Asia and the top medical institutions in the United States, HM Capital invests in the medical and health ecosystem in a multi-dimensional and three-dimensional way, and is committed to building a professional investment platform with an international perspective to help more early and growing medical and health enterprises achieve rapid growth. The main investment directions include biomedicine, medical services, medical devices, in vitro diagnosis, medical IT, etc.
About Qianhai Parent Fund
Qianhai Parent Fund was founded in 2016, with a scale of RMB 28.5 billion. It is currently the largest commercialized parent fund and a leading private equity investment fund in China. It pays equal attention to fund investment and direct equity investment, and is managed by Qianhai Fangzhou Asset Management Co., Ltd., led by Jin Haitao, the leader of Chinese venture capital. Since the establishment of Qianhai Parent Fund, a total of 1,300 direct/indirect equity projects have been invested, and more than 54 companies have been listed at home and abroad.
About Yuansheng Venture Capital
Yuansheng Venture Capital is an investment institution focusing on the early and growing medical and health fields, which is based in Suzhou bioBAY and radiates all over the world. At present, the scale of management funds is about 5 billion RMB, and more than 90 high-quality projects have been invested, mainly involving new drug creation, medical devices, in vitro diagnosis, medical services and other fields, which have achieved rich investment returns, and have been selected as the Top10 Venture Capital Fund in China's medical and health field and the most active medical and health investment institution in China for many times. Yuansheng Venture Capital brings together a team of senior professional investors and the world's top scientific consultants, and has rich experience in entrepreneurship, venture capital and enterprise operation in biomedicine and other industries. Through dedicated and abundant industry resources, Yuansheng Venture Capital is determined to develop into one of the most successful medical and pharmaceutical venture capital funds in China. About Haoyue Capital Haoyue Capital, founded in January 2014, is committed to serving as a bridge between Chinese medical care and capital. The research field and transaction scope of Haoyue Capital cover many sub-sectors such as biomedicine, innovative medical devices, IVD and precision medicine, medical service and smart medicine. The team of Haoyue Capital is composed of senior investment bankers who have been deeply involved in China's medical and health field for many years. It closely tracks the market dynamics and investment trends of medical and health investment for a long time, and publishes weekly medical and health investment reports and special research reports every week to interpret new policies and new frontiers from the viewpoint of Haoyue.